Trial Profile
Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Gabapentin (Primary)
- Indications Cerebellar ataxia; Multiple sclerosis
- Focus Therapeutic Use
- Acronyms GABATAX
- 01 Jun 2016 Status changed from recruiting to completed.
- 26 Aug 2011 New source identified and integrated (German Clinical Trials Register; DRKS00000269).
- 03 Aug 2011 New trial record